Stock-based compensation expense: what founders miss in the books

Every option grant creates a monthly P&L expense whether or not cash moves. Here is what it is, how to calculate it, and what happens when the books miss it.

A biotech CFO we work with got a call from her auditors six weeks before the Series B close. The question was direct: where was the stock-based compensation expense for the prior two years? She had the option grant agreements, the 409A valuations, and the cap table updated every month. The books showed $0 in compensation expense across 247,000 options that had been vesting for 24 months. The auditors flagged a restatement of $1.04 million.

What stock-based compensation expense is

Stock-based compensation expense is a non-cash expense required by the standard accounting method auditors expect (GAAP). Any company that grants stock options or restricted stock units (RSUs) to employees or contractors must record it on the Profit and Loss report (P&L). No cash changes hands when the entry is posted. That is exactly why founders miss it. The option agreement sits in a file. The cap table tracks ownership. But the books never see the entry unless a bookkeeper builds it manually each month.

Why the expense is missing

The grant agreement shows the exercise price, not the expense. The document says “150,000 shares at $2.80 per share.” The $2.80 is the exercise price, set at the common stock fair market value on the grant date based on the 409A valuation (an independent appraisal of the company’s common stock, required by the IRS before options can be granted). It is not the recorded expense. The expense is the fair value of the option itself, calculated using a model called Black-Scholes, which accounts for the exercise price, the current share price, the expected option term, expected volatility, and the risk-free interest rate. That calculation produces a separate per-option value, not a direct read from the agreement.

The vesting schedule, not the grant date, drives when expense enters the books. Options typically vest over four years with a one-year cliff: 25 percent at the one-year anniversary, then monthly through year four. Expense is recognized over that same period. On a grant with a total fair value of $420,000, the first $105,000 is recognized at month 12, and $8,750 is recognized each month from month 13 through month 48.

Each grant requires its own schedule. A biotech that has issued five option grants to four employees over 18 months has five separate schedules, each with a different grant date, fair value per option, vesting start, and monthly expense. The total monthly stock-based compensation expense is the sum of all active schedules. Without a maintained file, the monthly total is unknown and the books understate it.

The journal entry has no matching invoice. Most expenses in QuickBooks arrive as vendor bills, bank feed entries, or credit card charges. Stock-based compensation has none of those. The entry is created manually each month: debit Compensation Expense, credit Additional Paid-In Capital (an equity account on the balance sheet that records the value shareholders have put into the company beyond par value). Because no cash moves and no vendor bill arrives, the entry requires a standing close checklist item to stay current.

What one grant schedule looks like

Here is how one option grant translates from agreement to journal entry.

A research director received 150,000 options on January 1, 2024. The 409A valuation in effect on that date set common stock fair market value at $2.80 per share, so the exercise price was $2.80. Black-Scholes produced a fair value of $2.80 per option. Vesting: four years, one-year cliff.

Item	Amount
Options granted	150,000
Black-Scholes fair value per option	$2.80
Total grant date fair value	$420,000
Expense recognized at month 12 (cliff)	$105,000
Monthly expense: months 13 through 48	$8,750
Total lifetime expense	$420,000

The entry from month 13 onward: debit Research and Development Compensation $8,750, credit Additional Paid-In Capital $8,750. At month 48, the full $420,000 has been recognized.

Why missing expense creates real problems

The books overstate profitability. A pre-revenue biotech showing a $200,000 operating loss may actually be running at a $308,750 loss once the current month of option expense is added. Board members and investors reading the P&L are working from incomplete numbers and making capital allocation decisions accordingly.

Auditors require restatement. Any audit tied to a Series A close, a Series B close, or a grant milestone will surface the omission. Restating multiple years of financials adds weeks to a round close and direct out-of-pocket cost. One company we have worked with needed six weeks and $40,000 in additional audit fees to restate three years of option expense before a deal could close.

What accurate books look like

For life sciences clients we work with, stock-based compensation runs on a standing process.

When a new grant closes, we request the grant date, the 409A report in effect on that date, the number of options, and the vesting terms. We verify the Black-Scholes fair value and build a month-by-month expense schedule from grant date through full vesting. That schedule is stored in a shared file.

On the first business day of each month, the total expense from all active schedules is posted as a journal entry in QuickBooks. Research staff options go to Research and Development. Administrative and executive options go to General and Administrative. When an employee departs before vesting, the unvested expense is reversed in the month of termination.

Best practices for managing option expense

Four practices that keep the expense accurate over time:

Build the Black-Scholes schedule within 30 days of each grant date. Do not wait until audit season. The inputs shift over time, and retroactive calculations become disputes.
Maintain one master file listing every active grant, the monthly expense per grant, and the cumulative amount recognized to date. Update it when grants are issued, employees leave, or options are repriced or cancelled.
Add the stock-based compensation journal entry to the standard month-end close checklist. A quarterly or annual catch-up produces distorted period-over-period results that need to be explained to investors.
Split R&D and G&A expense from the start. Research staff options belong in research and development expense. Mixing them with general and administrative expense distorts the R&D line that clinical-stage investors and grant reviewers examine closely.

Three questions worth asking

If you are not certain whether the books reflect option expense correctly, three questions to ask:

What is the total stock-based compensation expense in the books for the last 12 months, and does that figure match the sum of all active grant schedules?
For each grant issued in the last two years, has the Black-Scholes fair value been documented and entered into a vesting schedule?
Has any employee left before fully vesting, and was the unvested expense reversed in the month they departed?

If the answers are uncertain, the books likely carry a growing restatement risk. The fix is a spreadsheet and a recurring journal entry.

If you want a second opinion before an audit or round close, send us the current option grant schedule and the last two months of journal entries. We will confirm whether the expense is being recognized on the right schedule and whether the R&D and G&A splits match the actual allocation.